-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SL-701 in High-Grade Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SL-701 in High-Grade Glioma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SL-701 in High-Grade Glioma Drug Details: SL-701 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SL-701 in Low-Grade Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SL-701 in Low-Grade Glioma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SL-701 in Low-Grade Glioma Drug Details: SL-701 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DLQ-02 in Plaque Psoriasis (Psoriasis Vulgaris)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DLQ-02 in Plaque Psoriasis (Psoriasis Vulgaris) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DLQ-02 in Plaque Psoriasis (Psoriasis Vulgaris) Drug Details: DLQ-02...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Regorafenib in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Regorafenib in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Regorafenib in Gastric Cancer Drug Details: Regorafenib (BAY 73-4506, Stivarga) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Regorafenib in Esophageal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Regorafenib in Esophageal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Regorafenib in Esophageal Cancer Drug Details: Regorafenib (BAY 73-4506, Stivarga) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Regorafenib in Rhabdomyosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Regorafenib in Rhabdomyosarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Regorafenib in Rhabdomyosarcoma Drug Details: Regorafenib (BAY 73-4506, Stivarga) is an anti-neoplastic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Regorafenib in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Regorafenib in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Regorafenib in Adenocarcinoma Of The Gastroesophageal Junction Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pritumumab in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pritumumab in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pritumumab in Non-Small Cell Lung Cancer Drug Details: Pritumumab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Regorafenib in Metastatic Hepatocellular Carcinoma (HCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Regorafenib in Metastatic Hepatocellular Carcinoma (HCC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Regorafenib in Metastatic Hepatocellular Carcinoma (HCC) Drug Details: Regorafenib...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Trabedersen in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Trabedersen in Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Trabedersen in Pancreatic Cancer Drug Details: Trabedersen (OT-101) is under development...